Redefining the geography of pharmaceutical innovation: Kelly Chibale as a harbinger for integrated drug discovery in Africa

1 Introduction

For most of the 20th century, drug discovery capacity was concentrated in North America, Western Europe, and parts of East Asia, where industrial pharmaceutical laboratories and well-resourced academic centres dominated target identification, high-throughput screening, medicinal chemistry, and translational pharmacology (Singh et al., 2022). This geographic concentration created a persistent asymmetry in the global pharmaceutical ecosystem, particularly evident in sub-Saharan Africa, a region that bears a disproportionate burden of infectious diseases yet has historically contributed primarily epidemiological insight, clinical trial infrastructure, and biological samples rather than early-stage molecular innovation (Singh et al., 2022; Mayoka and Cheuka, 2025).

This centralisation produced a structural paradox: diseases such as malaria and tuberculosis, which predominantly affect African populations, were addressed through discovery pipelines largely designed, made, and optimised outside the continent. The late 1990s and early 2000s marked an inflection point, driven by the emergence of product development partnerships, philanthropic funding mechanisms, and increased global attention to health inequities. Within this evolving landscape, Kelly Chibale emerged as a transformative figure, advancing a vision that extended beyond participation in global drug discovery networks toward the establishment of endogenous African capacity. This vision culminated in the creation of the H3D Centre, the continent’s first fully integrated drug discovery platform, enabling end-to-end discovery-to-clinic progression and reshaping the institutional architecture of African innovative pharmaceutical research (Mayoka and Cheuka, 2025).

Over the past 2 decades, this model has expanded beyond a single centre into the Grand Challenges African Drug Discovery Accelerator (GC ADDA), reflecting a shift from localised excellence to a distributed, network-based innovation ecosystem. This article examines Prof. Chibale’s contributions across drug discovery underpinned by medicinal chemistry innovation, institutional development, ecosystem catalysis, and multinational consortium building, arguing that his legacy lies in redefining the geography of pharmaceutical innovation and advancing a collaborative framework for scientific sovereignty and sustainable drug discovery in the Global South.

2 Kelly Chibale’s scientific foundations: synthetic organic chemistry, medicinal chemistry and translational milestones

2.1 About Kelly Chibale

Professor Kelly Chibale (Figure 1) is a pioneering African synthetic organic and medicinal chemist whose work has fundamentally reshaped the continent’s role in global drug discovery by combining scientific excellence with institution-building and ecosystem development. Trained in chemistry in Zambia, the United Kingdom (including as a visiting fellow at Pfizer in Sandwich), and United States of America, he specialised in small-molecule drug discovery for cardiovascular disease, including hypertension and well as infectious diseases, with a particular focus on malaria, tuberculosis, schistosomiasis and more recently on antibiotic-resistant microbial diseases. Notably his team’s antimalarial drug discovery research has advanced novel compounds toward clinical development (Phillips et al., 2015; Gilden, 2021; Siqueira-Neto et al., 2023; Veale et al., 2023; Dziwornu et al., 2026). His most transformative achievement is the founding in 2010 of the Holistic Drug Discovery and Development (H3D) Centre at the University of Cape Town, the first fully integrated drug discovery platform in Africa, which brought together biology, chemistry, and pharmacology, including drug metabolism and pharmacokinetics (DMPK), and translational capabilities within a single African institution. Through H3D, he demonstrated that high-quality pharmaceutical innovation—from hit identification to clinical candidate progression—can be achieved on the continent, shifting Africa’s role from a passive site of sample collection and clinical trials to an active originator of potential new medicines. Beyond a single centre, Prof. Chibale has extended this vision across the continent through his leadership of the GC ADDA (https://www.gcadda.org/) network, a pan-African initiative that connects research institutions, provides mentorship, and supports early-stage drug discovery. Equally important is his role in training a new generation of African innovative pharmaceutical scientists, helping build sustainable human capacity and reducing reliance on external expertise. His contributions have earned global recognition and influenced science policy, positioning Africa as an emerging hub for pharmaceutical innovation. Ultimately, Prof. Chibale’s legacy lies not only in molecules discovered but in establishing a scalable model for African-led, globally competitive drug discovery.

2.2 Antiparasitic drug discovery as a strategic entry point: case of antimalarial discovery

Prof. Chibale’s scientific contributions are firmly rooted in small-molecule drug discovery targeting malaria, tuberculosis, antibiotic-resistant microbial diseases and neglected tropical diseases, an area that combines urgent public health needs with significant scientific complexity. As a starting point, malaria offered both a compelling challenge and a strategic opportunity: it is highly endemic in Africa, biologically intricate, and increasingly supported by global funding and collaborative frameworks aimed at accelerating therapeutic innovation. Moreover, as a child, Prof. Chibale himself suffered several bouts of malaria including a severe one that was almost fatal. Within this context, his research programs have been distinguished by a rigorous, systematic approach to drug discovery underpinned by medicinal chemistry. Central to this has been the iterative refinement of structure–activity relationships (SAR), enabling the progressive optimisation of compound potency and selectivity. This process has been complemented by careful tuning of physicochemical properties to enhance drug-likeness, solubility, and permeability. Importantly, his work has emphasised the early integration of absorption, distribution, metabolism, and excretion (ADME) profiling (Tukulula et al., 2013), ensuring that compounds are evaluated not only for biological activity but also for their behaviour in biological systems. By aligning compound optimisation with clearly defined target product profiles (TPPs), his programs have maintained a strong translational focus from the outset. This holistic approach—combining chemical design, biological and pharmacological evaluation, and pharmacokinetic insight—has enabled projects at the H3D Centre to operate with a level of rigour comparable to industrial drug discovery environments, demonstrating that high-quality, end-to-end pharmaceutical innovation can be successfully conducted within an African academic setting. Prof. Chibale’s contributions are not just limited to infectious diseases. He has also contributed to the fight against cardiovascular disease, including hypertension through the design and synthesis of small-molecule domain selective inhibitors of angiotensin-I converting enzyme (ACE). In addition to several co-authored publications in this field, he is a co-inventor of ACE inhibitor patents around which Angiodesign (https://angiodesign.com/), a spin out company registered in the United Kingdom, was established.

2.3 Advancement of a home-grown clinical candidate

A defining milestone in African drug discovery was the advancement of MMV390048, a novel first-in class small-molecule Plasmodium phosphatidylinositol 4-kinase inhibitor, from an international effort led out of Africa at the H3D Centre, in partnership with the Medicines for Malaria Venture (MMV) into translational First-In-Human studies conducted at the University of Cape Town and then subsequently phase 2 human clinical trials (Sinxadi et al., 2020; Singh et al., 2022). In a landscape where many African drug discovery efforts have historically been fragmented, H3D demonstrated the ability to generate integrated outputs spanning the full spectrum from hit identification to advanced lead optimisation. This achievement provided clear evidence that African laboratories can compete effectively in global pharmaceutical innovation. The significance of this milestone is multidimensional. Scientifically, it demonstrated a functional and coherent hit-to-lead discovery capability within an African setting. Institutionally, it validated the H3D operational model as a sustainable and effective platform for end-to-end drug discovery. Symbolically, it marked a paradigm shift by proving that Africa can originate pharmaceutical innovation, rather than serving solely as a site for clinical trials and downstream validation.

2.4 Methodological strategy: phenotypic screening and rational optimisation

Malaria drug discovery has frequently relied on phenotypic screening due to the complexity of parasite biology and challenges in target validation (Hovlid and Winzeler, 2016). H3D’s strategy combined whole-cell phenotypic screening with rational medicinal chemistry refinement, balancing empirical screening with mechanistic insight, as well target-based drug discovery and conduct target deconvolution to elucidate the mechanism of action of phenotypic hits. This pragmatic methodological stance allowed the centre to compete effectively within global malaria discovery initiatives.

3 Institutional architecture: the H3D model and its ripple effect

The founding of the H3D Centre introduced structural innovation within African science ecosystems. Beyond its internal capabilities, H3D has served as a powerful proof-of-concept that integrated, end-to-end drug discovery can be successfully implemented within an African academic environment. This success has inspired the emergence of similar initiatives across the continent, including the University of Buea Centre for Drug Discovery in Cameroon, which is building capacity in natural product–based drug discovery and medicinal chemistry, and the Drug Innovation Group at the University of Ghana, which is advancing small-molecule research and translational training in West Africa. In Southern Africa, the Africa Centre for Therapeutics Innovation (ACTI) represents a complementary model that bridges early discovery, and clinical development. These emerging centres, though diverse in focus and scale, share a common influence: the H3D model, which integrates multidisciplinary expertise, aligns research with translational goals, and fosters strategic partnerships. Collectively, they signal a growing continental shift from isolated research efforts to coordinated, innovation-driven drug discovery ecosystems rooted in African leadership. Other budding efforts on the continent include drug discovery teams at the Kenya Medical Research Institute (KEMRI), University of Zambia, University of KwaZulu-Natal and Rhodes University, among others. While H3D demonstrated that integrated drug discovery was feasible in Africa, a single centre could not address the continent’s capacity gaps. The logical next step was network expansion, which has been rolled out across the GC ADDA network.

3.1 Integrated platform design

The H3D Centre was established as an integrated, pipeline-oriented drug discovery platform, consolidating key capabilities including screening technologies, biology, medicinal chemistry, in vitro ADME systems, drug metabolism and pharmacokinetics (DMPK), early safety and toxicology assessment, and translational project management (Winks et al., 2022). By co-locating these functions within a single institutional framework, H3D enables seamless progression from hit identification to lead optimisation and candidate selection. Unlike fragmented, grant-driven research laboratories, this model supports iterative, data-driven decision-making and sustained program development. The result is a cohesive discovery environment capable of delivering translational outputs that meet industry-level standards while being rooted within an African academic context.

3.2 Hybrid funding strategy

Sustainability at the H3D Centre was achieved through a diversified funding model combining government, philanthropic foundations, product development partnerships, bilateral industry collaborations, and competitive international grants (Winks et al., 2022). This hybrid architecture minimised dependence on a single funding source, reduced financial vulnerability, and enabled long-term strategic planning, supporting the continuity and growth of integrated drug discovery programs.

3.3 Academia–industry partnership redefined

The H3D Centre positioned African scientists as equal intellectual partners in global drug discovery collaborations. Negotiations were structured around co-development rather than subcontracting, ensuring shared ownership of scientific direction and outcomes. This recalibration of partnership dynamics was critical for institutional confidence and long-term sustainability. It also enabled more balanced decision-making, with African investigators contributing meaningfully to strategic priorities and project design (Winks et al., 2025). Furthermore, these partnerships facilitated access to advanced technologies, industry-standard workflows, and global development expertise. Collectively, this model strengthened the credibility of African institutions as reliable and competitive contributors to international pharmaceutical research.

4 From centre to continent: the formation of the GC ADDA consortium

The conception and birth of GC ADDA was preceded by seed funding from the Gates Foundation (Grand Challenges Africa) under drug discovery in 2018 and 2020 to 16 scientists across Africa (https://gcgh.grandchallenges.org/challenge/grand-challenges-africa-drug-discovery). The projects aimed at structured, collaborative drug discovery across Africa through initiatives between African scientists and international partners. The awardees included African investigators working in African-based, domestic, or non-profit organizations, including research and academic institutions.

This program was set up to address long-standing gaps in infrastructure, training, and funding by supporting multidisciplinary, project-driven research focused on diseases of regional importance such as malaria and tuberculosis. It enabled the initial grantees to identify and optimize new chemical entities while strengthening institutional capacity and fostering intra-African and global collaborations. By linking researchers to shared expertise, mentorship, and advanced technologies, the initiative was aimed at enhancing scientific quality, reducing fragmentation, and promoting sustainable, networked drug discovery ecosystems across the continent. Many of the initial grantees from this programme were among the founding members of the GC ADDA network.

4.1 Conceptual rationale for GC ADDA

The Grand Challenges African Drug Discovery Accelerator emerged as a strategic response to two key challenges: fragmented expertise across African institutions and a lack of mechanisms to accelerate promising projects toward translational milestones. Rather than replicating the H3D Centre across multiple locations, GC ADDA adopted a distributed accelerator model that links centres of excellence, industry mentors, and funding pipelines. This approach enables coordinated support for high-potential projects while leveraging complementary strengths across the continent. Current flagship projects span therapeutic areas such as malaria and tuberculosis drug discovery, a DMPK centre of excellence, and a collection of African-based natural products for screening, thereby reflecting Africa’s disease priorities. Collectively, these initiatives demonstrate how a networked model can efficiently translate early-stage discoveries into viable drug development pipelines.

4.2 Structural design and strategic importance of GC ADDA

GC ADDA was established by the H3D Foundation (https://h3dfoundation.org/) with funding support from the Gates Foundation and LifeArc. It operates as a pan-African consortium (with representation in four of the 5 geographical regions of Africa, Figure 2), an accelerator framework, and a translational support platform, all designed to strengthen drug discovery across the continent. Its structure integrates competitive project selection, milestone-driven funding, and access to critical expertise in medicinal chemistry and drug metabolism and pharmacokinetics (DMPK), complemented by industry mentorship and translational guidance.

By coordinating these elements, GC ADDA minimises duplication of efforts while leveraging distributed expertise across multiple institutions. Importantly, the accelerator model directly addresses the persistent “valley of death” in African drug discovery, where promising academic hits often fail to progress due to limited resources for optimisation and development. Through structured mentorship, technical support, and adherence to industry-standard workflows, GC ADDA enables systematic progression from early discovery to advanced lead stages. Clear go/no-go decision criteria further ensure efficient resource allocation and project prioritisation. This integrated and networked approach not only enhances the quality and competitiveness of African-led research but also creates a sustainable pathway for translating scientific discoveries into viable drug development pipelines aligned with continental health priorities.

4.3 Continental network effects

Although initial success is hard to measure, GC ADDA catalyses cross-border collaborations, South–South partnerships, increased visibility for African-led projects, and the standardisation of translational benchmarks across drug discovery programs. Integrating institutions across multiple African regions strengthens coordination and knowledge exchange among diverse research groups. This networked structure enables more efficient sharing of expertise and resources while fostering alignment with global drug development standards. Collectively, GC ADDA represents a decisive shift from centralised excellence to a distributed, collaborative innovation ecosystem across the African continent.

4.4 Strengthening health innovation ecosystems

The establishment of the H3D Centre represented a major step toward strengthening health innovation ecosystems in Africa by demonstrating how integrated, collaborative, and translationally oriented research platforms can address longstanding structural weaknesses in pharmaceutical R&D (Binder et al., 2021; Bucio-Mendoza and Solís-Navarrete, 2025). Much like the innovation shifts observed during the COVID-19 pandemic, H3D adopted a model that combines public, academic, philanthropic, and industry partnerships to accelerate product development while building sustainable local capacity (Daum et al., 2025). Beyond scientific discovery, H3D has contributed to broader ecosystem strengthening through training, technology transfer, and the development of collaborative networks linking academia, public health institutions, funders, and private-sector partners. Its influence is reflected in initiatives such as the Grand Challenges African Drug Discovery Accelerator (GC ADDA), which extends these principles continent-wide through distributed innovation and mentorship frameworks (Sampat and Shadlen, 2021). Similar to emerging social innovation ecosystems described in global health and development literature, H3D integrates flexible governance, multidisciplinary collaboration, and shared infrastructure to support resilient and locally driven pharmaceutical innovation (Vieira et al., 2023). In doing so, it has helped position African institutions not merely as participants in global health responses but as active drivers of scientific innovation, translational research, and long-term health system resilience. One would, therefore, interpret H3D and GC ADDA not only as successful initiatives but as a genuine pharmaceutical innovation ecosystem that brings together knowledge, funding, infrastructure, talent development, and international cooperation.

5 Mentorship and human capital multiplication

The multiplicative effect of human capital formation measures the impact of generational leadership. Through H3D and GC ADDA, Chibale has contributed to:

• - Training doctoral and postdoctoral medicinal chemists
• - Developing translational project managers
• - Exposing African scientists to industrial workflows
• - Building confidence in African-led R&D

GC ADDA extends mentorship beyond H3D trainees, democratizing access to high-level translational expertise across the continent. Besides, H3D also runs a Global Health Mentorship Programme that includes young African scientists being mentored by Associates (often drawn from scientists with industry-level drug discovery experience to help in fostering drug discovery in Africa (Winks et al., 2022).

6 Scientific sovereignty and distributed R&D

Scientific sovereignty refers to the capacity to define research priorities, control early-stage intellectual property, negotiate partnerships from a position of strength, and retain technical knowledge within local institutions. The combined H3D Centre and GC ADDA architecture operationalises this concept through collaborative rather than isolated frameworks. Linking African institutions into coordinated networks strengthens autonomy while maintaining global engagement. In the context of AI-assisted molecular design, open innovation ecosystems, and distributed pharmaceutical R&D, such geographically diversified models enhance scientific resilience, responsiveness, and long-term sustainability of drug discovery capacity (https://h3dfoundation.org/current-initiatives/gc-adda/).

7 Lessons for the global South and future outlook: African drug discovery in ten years

Drug discovery in Africa offers transferable principles for the broader Global South, including the importance of building integrated platforms rather than fragmented laboratories, prioritising mentorship as core scientific infrastructure, combining strong local leadership with meaningful global partnerships, using accelerator models to bridge translational gaps, and anchoring scientific sovereignty in demonstrated competence rather than rhetoric. These principles extend beyond Africa, providing relevant guidance for regions such as Latin America and Southeast Asia seeking to strengthen their drug discovery ecosystems. Looking toward 2035, drug discovery in Africa is expected to evolve significantly, with increasing integration of AI-enabled medicinal chemistry, the development of pan-African digital and physical compound libraries, improved regulatory harmonisation, and a rise in African-led clinical development programs (Somdyala, 2024). Expanded cohorts within GC ADDA, building on the foundation laid by the H3D Centre, position Africa to transition from an emerging participant to a strategic contributor in global pharmaceutical innovation pipelines.

8 Conclusion

The legacy of Prof. Kelly Chibale lies not only in the compounds advanced but also in the systems constructed. Through H3D, he demonstrated that integrated drug discovery could thrive in Africa. Through GC ADDA, most of whose current members have at some point in their career been mentored by Kelly, he extended that vision across the continent. In redefining where drug discovery can occur, Prof. Chibale has altered the intellectual geography of pharmaceutical innovation. His generational impact resides in normalising African-led molecular innovation and establishing a scalable blueprint for distributed, sovereign, and collaborative drug discovery in the Global South.

Generative AI statement

The author(s) declared that generative AI was not used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Footnotes

Edited by: Jose Correa Basurto, Escuela Superior de Medicina (IPN), Mexico

Reviewed by: Jose Alberto Solis-Navarrete, National Autonomous University of Mexico, Mexico

Dibyajyoti Saikia, All India Institute of Medical Sciences, Guwahati, India